Too much fat released from belly fat or made by the liver itself clogs liver cells, triggers inflammation, and makes the liver less responsive to insulin.
Scientific Claim
Elevated free fatty acids (FFAs) from visceral adipose tissue and de novo lipogenesis are associated with hepatic lipid accumulation and insulin resistance in obese individuals, as excess FFAs activate inflammatory pathways like NF-κB and impair insulin signaling in hepatocytes.
Original Statement
“Free fatty acids derived from VAT tissue, as well as from dietary sources and de novo lipogenesis, are released to the portal venous system. Excess free fatty acids and chronic low-grade inflammation from VAT are considered to be two of the most important factors contributing to liver injury progression in NAFLD. Free fatty acids are able to activate this pathway in the liver, and increase hepatic diacylglycerol (DAG) content, the activity of protein kinase C-delta and plasma levels of monocyte chemoattractant protein-1 (MCP-1), thus explaining the VAT-induced FFA increase in hepatic circulation that leads to chronic low-grade inflammation and IR in fatty liver.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim relies on animal models and human observational data; while mechanisms are plausible, the review does not prove causation in humans. Verbs like 'contribute to' and 'explain' imply causal roles beyond the evidence.
More Accurate Statement
“Elevated free fatty acids from visceral adipose tissue and de novo lipogenesis are associated with hepatic lipid accumulation and insulin resistance in obese individuals, potentially through activation of NF-κB signaling and increased diacylglycerol content in hepatocytes.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether reducing portal FFA flux (via VAT-targeted intervention) directly improves hepatic insulin sensitivity and reduces liver fat in obese humans.
Whether reducing portal FFA flux (via VAT-targeted intervention) directly improves hepatic insulin sensitivity and reduces liver fat in obese humans.
What This Would Prove
Whether reducing portal FFA flux (via VAT-targeted intervention) directly improves hepatic insulin sensitivity and reduces liver fat in obese humans.
Ideal Study Design
A 6-month double-blind RCT of 100 obese adults with NAFLD and elevated portal FFA (measured by hepatic vein catheterization) randomized to: (1) selective VAT reduction via bariatric surgery, or (2) matched weight loss via diet; primary outcomes: change in hepatic insulin sensitivity (hyperinsulinemic-euglycemic clamp) and liver fat (MRI-PDFF).
Limitation: Cannot isolate FFA effects from other metabolic changes post-surgery.
Prospective Cohort StudyLevel 2aWhether baseline plasma FFA levels predict progression to NASH or fibrosis over time in obese individuals.
Whether baseline plasma FFA levels predict progression to NASH or fibrosis over time in obese individuals.
What This Would Prove
Whether baseline plasma FFA levels predict progression to NASH or fibrosis over time in obese individuals.
Ideal Study Design
A 5-year prospective cohort of 800 obese adults with NAFLD, measuring fasting and postprandial plasma FFAs annually, with liver biopsy or FibroScan at baseline and endpoint to assess fibrosis progression.
Limitation: Cannot prove FFA is the direct driver vs. a marker of metabolic dysfunction.
Animal Model StudyLevel 4In EvidenceWhether experimentally increasing portal FFA delivery directly induces hepatic inflammation and insulin resistance independent of obesity.
Whether experimentally increasing portal FFA delivery directly induces hepatic inflammation and insulin resistance independent of obesity.
What This Would Prove
Whether experimentally increasing portal FFA delivery directly induces hepatic inflammation and insulin resistance independent of obesity.
Ideal Study Design
A study in 40 C57BL/6 mice with surgically created porto-systemic shunts to increase hepatic FFA delivery, compared to sham controls, on a high-fat diet; measuring liver DAG, NF-κB activation, insulin signaling (Akt phosphorylation), and inflammation markers.
Limitation: Does not translate directly to human physiology or disease progression.
Cross-Sectional StudyLevel 3In EvidenceWhether hepatic DAG content correlates with plasma FFA levels and insulin resistance in humans with NAFLD.
Whether hepatic DAG content correlates with plasma FFA levels and insulin resistance in humans with NAFLD.
What This Would Prove
Whether hepatic DAG content correlates with plasma FFA levels and insulin resistance in humans with NAFLD.
Ideal Study Design
A cross-sectional study of 150 obese adults with biopsy-proven NAFLD, measuring liver DAG via mass spectrometry, plasma FFAs via HPLC, and insulin resistance via HOMA-IR, adjusting for BMI and liver fat content.
Limitation: Cannot determine directionality or causality.
Evidence from Studies
Supporting (1)
Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
This study shows that when people are obese, especially with fat around their belly, their bodies release too many fatty acids into the liver, which causes fat buildup and inflammation, making the liver less responsive to insulin — just like the claim says.